The Longevity Reality Radar
46 approaches, rated by evidence.

HIV functional cure

HIV functional cure (bnAb CAR-T / broadly neutralizing antibodies). Infectious disease. Reviewed Jul 2026.

Reservoir reduction in early human work and viral suppression in mice, still far from a routine cure.

Stage
Preclinical, early human work
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
C
early human, mice
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

Engineering long-lived immune cells or antibodies that keep HIV suppressed without daily drugs by attacking the viral reservoir.

The evidence

bnAb-derived CAR-T reduced the viral reservoir in early human work and suppressed HIV in humanized mice; Gilead is pairing bnAbs (teropavimab/zinlirvimab) with lenacapavir. Still far from routine cure.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Infectious disease

  • Lenacapavir PrEP (Yeztugo)Grade A, outcome RCTs. Approved.Randomised trials showed zero HIV infections among more than 2,100 women and about 96% lower incidence in a second trial.